IMVT
Immunovant, Inc.Healthcare · $6.9B market cap
Verdict
We can't put a fair value on IMVT right now. It has lost money in each of its last 3 years, and our valuation needs recent profits to project from.
Business quality
0 of 5 clear the 10% bar. What are the Big Five?
Follow IMVT
Track it on your watchlist and see the full analysis. Free.
Create a free accountInsider activity
Since Oct 21, 2026: no open-market purchases and 1 sale worth $75K. Why purchases matter
Sales
Questions about IMVT
Are insiders buying IMVT?
Since Oct 21, 2026: no open-market purchases and 1 sale worth $75K.
How can I check IMVT's value myself?
Use the free Sticker Price calculator, already filled with IMVT's numbers. Change the growth, P/E or required return and see what you'd pay. Open the calculator →
Similar stocks · Biotechnology
About Immunovant, Inc.
Immunovant, Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to advancing novel monoclonal antibody therapies for the treatment of various autoimmune conditions. The company's primary focus is batoclimab, a pioneering, fully human monoclonal antibody. This antibody is engineered to specifically target and block the neonatal fragment crystallizable receptor (FcRn), a key mechanism in certain autoimmune diseases. Batoclimab is currently undergoing Phase IIa clinical evaluations for treating both myasthenia gravis and thyroid eye disease. Additionally, it has commenced Phase II clinical studies for patients suffering from warm autoimmune hemolytic anemia. Established in 2018, Immunovant operates from its headquarters in New York, New York, functioning as a subsidiary under the umbrella of Roivant Sciences Ltd.
Biotechnology
Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of Oct 23, 2026. How the Payback Price works